These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29756566)

  • 1. Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD).
    Russo P; Prinzi G; Lamonaca P; Cardaci V; Fini M
    Curr Med Chem; 2019; 26(39):7048-7058. PubMed ID: 29756566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.
    Cazzola M; Calzetta L; Rinaldi B; Page C; Rosano G; Rogliani P; Matera MG
    Drugs; 2017 May; 77(7):721-732. PubMed ID: 28349353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease.
    Campo G; Pavasini R; Biscaglia S; Contoli M; Ceconi C
    Eur Heart J Cardiovasc Pharmacother; 2015 Jul; 1(3):205-11. PubMed ID: 27533997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.
    Brassington K; Selemidis S; Bozinovski S; Vlahos R
    Clin Sci (Lond); 2019 Apr; 133(7):885-904. PubMed ID: 30979844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease and COPD: dangerous liaisons?
    Rabe KF; Hurst JR; Suissa S
    Eur Respir Rev; 2018 Sep; 27(149):. PubMed ID: 30282634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic obstructive pulmonary disease and cardiovascular system].
    Gürgün A; Gürgün C
    Tuberk Toraks; 2008; 56(4):464-71. PubMed ID: 19123087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.
    Ferri C
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):103-11. PubMed ID: 25655487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease.
    Onishi K
    J Cardiol; 2017 Aug; 70(2):128-134. PubMed ID: 28325523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of comorbidities in COPD patients by disease severity in a German population.
    Greulich T; Weist BJD; Koczulla AR; Janciauskiene S; Klemmer A; Lux W; Alter P; Vogelmeier CF
    Respir Med; 2017 Nov; 132():132-138. PubMed ID: 29229085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge.
    Leong P; Macdonald MI; Ko BS; Bardin PG
    Med J Aust; 2019 May; 210(9):417-423. PubMed ID: 30907000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
    Brook RD; Anderson JA; Calverley PM; Celli BR; Crim C; Denvir MA; Magder S; Martinez FJ; Rajagopalan S; Vestbo J; Yates J; Newby DE;
    Heart; 2017 Oct; 103(19):1536-1542. PubMed ID: 28416587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Cardiovascular Comorbidity Influence the Prescribing of Bronchodilators in Chronic Obstructive Pulmonary Disease?
    Adesanoye DT; Willey CJ
    Ann Pharmacother; 2017 Oct; 51(10):855-861. PubMed ID: 28573879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular and chronic obstructive pulmonary diseases: pathophysiological processes and treatment tactics].
    Ambatiello LG; Chazova IE
    Ter Arkh; 2020 Apr; 92(3):78-83. PubMed ID: 32598797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease.
    Lin SH; Perng DW; Chen CP; Chai WH; Yeh CS; Kor CT; Cheng SL; Chen JJ; Lin CH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3051-3058. PubMed ID: 27980402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Markers of Inflammation and Oxidative Stress in COPD Patients with or without Cardiovascular Comorbidities.
    Kaźmierczak M; Ciebiada M; Pękala-Wojciechowska A; Pawłowski M; Nielepkowicz-Goździńska A; Antczak A
    Heart Lung Circ; 2015 Aug; 24(8):817-23. PubMed ID: 25797323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
    Wang MT; Liou JT; Lin CW; Tsai CL; Wang YH; Hsu YJ; Lai JH
    JAMA Intern Med; 2018 Feb; 178(2):229-238. PubMed ID: 29297057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine models of cardiovascular comorbidity in chronic obstructive pulmonary disease.
    Khedoe PP; Rensen PC; Berbée JF; Hiemstra PS
    Am J Physiol Lung Cell Mol Physiol; 2016 Jun; 310(11):L1011-27. PubMed ID: 26993520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-morbidity in COPD: the effects of cardiovascular drug therapies.
    Suissa S
    Respiration; 2010; 80(1):3-7. PubMed ID: 20551712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The place of β-adrenoblockers in the treatment of cardiovascular disease in patients with chronic obstructive pulmonary disease].
    Statsenko ME; Derevianchenko MV
    Kardiologiia; 2012; 52(12):57-63. PubMed ID: 23237442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk in chronic obstructive pulmonary disease.
    Maclay JD; McAllister DA; Macnee W
    Respirology; 2007 Sep; 12(5):634-41. PubMed ID: 17875049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.